# WILBUR

### Veterinary Report by Embark

embarkvet.com

Test Date: February 13th, 2019

### **Customer-supplied information**

Owner Name: NATHALIE BERNSTEIN Dog Name: Wilbur Sex: Male (intact) Date of birth: 11/23/17 (Estimated) Breed type: designer Breed: GOLDENDOODLE Breed registration: n/a Microchip: n/a

### Genetic summary

Genetic breed identification: Goldendoodle Predicted adult weight: **53 lbs** Calculated from 17 size genes.

#### Breed mix:



Genetic age: **32 human years** Human equivalent age based on size, date of birth provided, and other factors

## Karyogram (Chromosome painting)



## **Clinical Tools**

These clinical genetic tools can inform clinical decisions and diagnoses. These tools do not predict increased risk for disease.

#### Alanine Aminotransferase Activity (GPT)

• Wilbur's baseline ALT level is Low Normal

#### Why is this important to your vet?

Wilbur has one copy of a variant associated with reduced ALT activity as measured on veterinary blood chemistry panels. Please inform your veterinarian that Wilbur has this genotype, as ALT is often used as an indicator of liver health and Wilbur is likely to have a lower than average resting ALT activity. As such, an increase in Wilbur's ALT activity could be evidence of liver damage, even if it is within normal limits by standard ALT reference ranges.

#### What is Alanine Aminotransferase Activity?

Alanine aminotransferase (ALT) is a clinical tool that can be used by veterinarians to better monitor liver health. This result is not associated with liver disease. ALT is one of several values veterinarians measure on routine blood work to evaluate the liver. It is a naturally occurring enzyme located in liver cells that helps break down protein. When the liver is damaged or inflamed, ALT is released into the bloodstream.

#### How vets diagnose this condition

Genetic testing is the only way to provide your veterinarian with this clinical tool.

#### How this condition is treated

Veterinarians may recommend blood work to establish a baseline ALT value for healthy dogs with one or two copies of this variant.

## Health Report

#### How to interpret Wilbur's genetic health results:

If Wilbur inherited any of the variants that we tested, they will be listed at the top of the Health Report section, along with a description of how to interpret this result. We also include all of the variants that we tested Wilbur for that we did not detect the risk variant for.

#### A genetic test is not a diagnosis

This genetic test does not diagnose a disease. Please talk to your vet about your dog's genetic results, or if you think that your pet may have a health condition or disease.



#### Good news!

Wilbur is not at increased risk for the genetic health conditions that Embark tests.

14 variants not detected

**Additional Genetic Conditions** 

168 variants not detected



Wilbur did not have the variants that we tested for, that are relevant to his breeds:

- Son Willebrand Disease Type I (VWF)
- Progressive Retinal Atrophy, prcd (PRCD Exon 1)
- Solden Retriever Progressive Retinal Atrophy 1, GR-PRA1 (SLC4A3)
- Solden Retriever Progressive Retinal Atrophy 2, GR-PRA2 (TTC8)
- S Neuronal Ceroid Lipofuscinosis (CLN5 Golden Retriever Variant)
- SM2 Gangliosidosis (HEXB, Poodle Variant)
- Solution 2012 Degenerative Myelopathy, DM (SOD1A)
- Solution Neonatal Encephalopathy with Seizures, NEWS (ATF2)
- S Muscular Dystrophy (DMD Golden Retriever Variant)
- S Dystrophic Epidermolysis Bullosa (COL7A1)
- 🗸 Ichthyosis (PNPLA1)
- Solution Osteogenesis Imperfecta, Brittle Bone Disease (COL1A1)
- 📀 Osteochondrodysplasia, Skeletal Dwarfism (SLC13A1)
- Chondrodystrophy and Intervertebral Disc Disease, CDDY/IVDD, Type I IVDD (FGF4 retrogene -CFA12)



Wilbur did not have the variants that we tested for, in the following conditions that the potential effect on dogs with Wilbur's breeds may not yet be known.

- 🕑 MDR1 Drug Sensitivity (MDR1)
- S P2Y12 Receptor Platelet Disorder (P2Y12)
- Sector IX Deficiency, Hemophilia B (F9 Exon 7, Terrier Variant)
- S Factor IX Deficiency, Hemophilia B (F9 Exon 7, Rhodesian Ridgeback Variant)
- Sector VII Deficiency (F7 Exon 5)
- 📀 Factor VIII Deficiency, Hemophilia A (F8 Exon 10, Boxer Variant)
- Sector VIII Deficiency, Hemophilia A (F8 Exon 11, Shepherd Variant 1)
- Sector VIII Deficiency, Hemophilia A (F8 Exon 1, Shepherd Variant 2)
- 📀 Thrombopathia (RASGRP1 Exon 5, Basset Hound Variant)
- 🕑 Thrombopathia (RASGRP1 Exon 8)
- 📀 Thrombopathia (RASGRP1 Exon 5, American Eskimo Dog Variant)
- Von Willebrand Disease Type III, Type III vWD (VWF Exon 4)
- Son Willebrand Disease Type III, Type III vWD (VWF Exon 7)
- Canine Leukocyte Adhesion Deficiency Type I, CLADI (ITGB2)
- Canine Leukocyte Adhesion Deficiency Type III, CLADIII (FERMT3)
- Congenital Macrothrombocytopenia (TUBB1 Exon 1, Cairn and Norfolk Terrier Variant)
- Canine Elliptocytosis (SPTB Exon 30)
- Slanzmann's Thrombasthenia Type I (ITGA2B Exon 12)
- S May-Hegglin Anomaly (MYH9)
- S Prekallikrein Deficiency (KLKB1 Exon 8)
- S Pyruvate Kinase Deficiency (PKLR Exon 5)
- Service And Antician Contraction (In the Antician Contraction Cont
- Service Anticipation of the service of the service
- Service Anticipation of the service of the service

- 🔇 Pyruvate Kinase Deficiency (PKLR Exon 10)
- 🔇 Trapped Neutrophil Syndrome (VPS13B)
- 🔇 Ligneous Membranitis, LM (PLG)
- 📀 Congenital Hypothyroidism (TPO, Tenterfield Terrier Variant)
- 🛇 Complement 3 Deficiency, C3 Deficiency (C3)
- Severe Combined Immunodeficiency (PRKDC)
- S Severe Combined Immunodeficiency (RAG1)
- X-linked Severe Combined Immunodeficiency (IL2RG Variant 1)
- X-linked Severe Combined Immunodeficiency (IL2RG Variant 2)
- Section 21 Progressive Retinal Atrophy, rcd1 (PDE6B Exon 21 Irish Setter Variant)
- Progressive Retinal Atrophy, rcd3 (PDE6A)
- Progressive Retinal Atrophy, CNGA (CNGA1 Exon 9)
- C Progressive Retinal Atrophy (CNGB1)
- Progressive Retinal Atrophy (SAG)
- Second Se
- Service Retinal Atrophy, crd2 (IQCB1)
- Progressive Retinal Atrophy crd4/cord1 (RPGRIP1)
- ✓ X-Linked Progressive Retinal Atrophy 1, XL-PRA1 (RPGR)
- V Progressive Retinal Atrophy, PRA3 (FAM161A)
- Collie Eye Anomaly, Choroidal Hypoplasia, CEA (NHEJ1)
- 📀 Day blindness, Cone Degeneration, Achromatopsia (CNGB3 Exon 6)
- 🛇 Achromatopsia (CNGA3 Exon 7 German Shepherd Variant)
- S Achromatopsia (CNGA3 Exon 7 Labrador Retriever Variant)
- S Autosomal Dominant Progressive Retinal Atrophy (RHO)

- 🔇 Canine Multifocal Retinopathy (BEST1 Exon 2)
- 📀 Canine Multifocal Retinopathy (BEST1 Exon 5)
- 📀 Canine Multifocal Retinopathy (BEST1 Exon 10 Deletion)
- 📀 Canine Multifocal Retinopathy (BEST1 Exon 10 SNP)
- 🕑 Glaucoma (ADAMTS10 Exon 9)
- 🔮 Glaucoma (ADAMTS10 Exon 17)
- 🔮 Glaucoma (ADAMTS17 Exon 11)
- 🔇 Glaucoma (ADAMTS17 Exon 2)
- Hereditary Cataracts, Early-Onset Cataracts, Juvenile Cataracts (HSF4 Exon 9 Shepherd Variant)
- Primary Lens Luxation (ADAMTS17)
- Congenital Stationary Night Blindness (RPE65)
- S Macular Corneal Dystrophy, MCD (CHST6)
- 🔇 2,8-Dihydroxyadenine Urolithiasis, 2,8-DHA Urolithiasis (APRT)
- Cystinuria Type I-A (SLC3A1)
- 🗸 Cystinuria Type II-A (SLC3A1)
- 🗸 Cystinuria Type II-B (SLC7A9)
- S Hyperuricosuria and Hyperuricemia or Urolithiasis, HUU (SLC2A9)
- Selection of the select
- 📀 Primary Hyperoxaluria (AGXT)
- 📀 Protein Losing Nephropathy, PLN (NPHS1)
- S X-Linked Hereditary Nephropathy, XLHN (COL4A5 Exon 35, Samoyed Variant 2)
- S Autosomal Recessive Hereditary Nephropathy, Familial Nephropathy, ARHN (COL4A4 Exon 3)
- S Primary Ciliary Dyskinesia, PCD (CCDC39 Exon 3)
- Congenital Keratoconjunctivitis Sicca and Ichthyosiform Dermatosis, Dry Eye Curly Coat Syndrome, CKCSID (FAM83H Exon 5)

- 🗸 X-linked Ectodermal Dysplasia, Anhidrotic Ectodermal Dysplasia (EDA Intron 8)
- 🛇 Renal Cystadenocarcinoma and Nodular Dermatofibrosis, RCND (FLCN Exon 7)
- 🕑 Canine Fucosidosis (FUCA1)
- 🛇 Glycogen Storage Disease Type II, Pompe's Disease, GSD II (GAA)
- 🛇 Glycogen Storage Disease Type IA, Von Gierke Disease, GSD IA (G6PC)
- S Glycogen Storage Disease Type IIIA, GSD IIIA (AGL)
- 🔇 Mucopolysaccharidosis Type I, MPS I (IDUA)
- Mucopolysaccharidosis Type IIIA, Sanfilippo Syndrome Type A, MPS IIIA (SGSH Exon 6 Variant 1)
- Mucopolysaccharidosis Type IIIA, Sanfilippo Syndrome Type A, MPS IIIA (SGSH Exon 6 Variant 2)
- S Mucopolysaccharidosis Type VII, Sly Syndrome, MPS VII (GUSB Exon 5)
- S Mucopolysaccharidosis Type VII, Sly Syndrome, MPS VII (GUSB Exon 3)
- Glycogen storage disease Type VII, Phosphofructokinase Deficiency, PFK Deficiency (PFKM Whippet and English Springer Spaniel Variant)
- Glycogen storage disease Type VII, Phosphofructokinase Deficiency, PFK Deficiency (PFKM Wachtelhund Variant)
- ✓ Lagotto Storage Disease (ATG4D)
- Neuronal Ceroid Lipofuscinosis 1, NCL 1 (PPT1 Exon 8)
- Neuronal Ceroid Lipofuscinosis 2, NCL 2 (TPP1 Exon 4)
- S Neuronal Ceroid Lipofuscinosis 1, Cerebellar Ataxia, NCL4A (ARSG Exon 2)
- Veuronal Ceroid Lipofuscinosis 1, NCL 5 (CLN5 Border Collie Variant)
- Veuronal Ceroid Lipofuscinosis 6, NCL 6 (CLN6 Exon 7)
- Solution Neuronal Ceroid Lipofuscinosis 8, NCL 8 (CLN8 English Setter Variant)
- Neuronal Ceroid Lipofuscinosis (MFSD8)
- S Neuronal Ceroid Lipofuscinosis (CLN8 Australian Shepherd Variant)
- S Neuronal Ceroid Lipofuscinosis 10, NCL 10 (CTSD Exon 5)
- 🛇 Adult-Onset Neuronal Ceroid Lipofuscinosis (ATP13A2, Tibetan Terrier Variant)

- 🛇 GM1 Gangliosidosis (GLB1 Exon 15 Shiba Inu Variant)
- S GM1 Gangliosidosis (GLB1 Exon 15 Alaskan Husky Variant)
- 🕑 GM1 Gangliosidosis (GLB1 Exon 2)
- 🕑 GM2 Gangliosidosis (HEXA)
- 🛇 Globoid Cell Leukodystrophy, Krabbe disease (GALC Exon 5)
- Autosomal Recessive Amelogenesis Imperfecta, Familial Enamel Hypoplasia (Italian Greyhound Variant)
- 🛇 Persistent Mullerian Duct Syndrome, PMDS (AMHR2)
- 🛇 Deafness and Vestibular Syndrome of Dobermans, DVDob, DINGS (MYO7A)
- S Shar-Pei Autoinflammatory Disease, SPAID, Shar-Pei Fever (MTBP)
- 🛇 Alaskan Husky Encephalopathy, Subacute Necrotizing Encephalomyelopathy (SLC19A3)
- Alexander Disease (GFAP)
- Cerebellar Abiotrophy, Neonatal Cerebellar Cortical Degeneration, NCCD (SPTBN2)
- 🛇 Cerebellar Ataxia, Progressive Early-Onset Cerebellar Ataxia (SEL1L)
- Cerebellar Hypoplasia (VLDLR)
- Spinocerebellar Ataxia, Late-Onset Ataxia, LoSCA (CAPN1)
- Spinocerebellar Ataxia with Myokymia and/or Seizures (KCNJ10)
- 🕑 Hereditary Ataxia (RAB24)
- Senign Familial Juvenile Epilepsy, Remitting Focal Epilepsy (LGI2)
- Setal-Onset Neonatal Neuroaxonal Dystrophy (MFN2)
- Hypomyelination and Tremors (FNIP2)
- Shaking Puppy Syndrome, X-linked Generalized Tremor Syndrome (PLP)
- Veuroaxonal Dystrophy, NAD (Spanish Water Dog Variant)
- 🗸 L-2-Hydroxyglutaricaciduria, L2HGA (L2HGDH)
- 🛇 Polyneuropathy, NDRG1 Greyhound Variant (NDRG1 Exon 15)

- 🛇 Polyneuropathy, NDRG1 Malamute Variant (NDRG1 Exon 4)
- 🔇 Narcolepsy (HCRTR2 Intron 6)
- Progressive Neuronal Abiotrophy, Canine Multiple System Degeneration, CMSD (SERAC1 Exon 15)
- Progressive Neuronal Abiotrophy, Canine Multiple System Degeneration, CMSD (SERAC1 Exon 4)
- Juvenile Laryngeal Paralysis and Polyneuropathy, Polyneuropathy with Ocular Abnormalities and Neuronal Vacuolation, POANV (RAB3GAP1, Rottweiler Variant)
- 🛇 Hereditary Sensory Autonomic Neuropathy, Acral Mutilation Syndrome, AMS (GDNF-AS)
- S Juvenile-Onset Polyneuropathy, Leonberger Polyneuropathy 1, LPN1 (LPN1, ARHGEF10)
- 🗸 Juvenile Myoclonic Epilepsy (DIRAS1)
- S Juvenile-Onset Polyneuropathy, Leonberger Polyneuropathy 2, LPN2 (GJA9)
- Spongy Degeneration with Cerebellar Ataxia 1, SDCA1, SeSAME/EAST Syndrome (KCNJ10)
- Spongy Degeneration with Cerebellar Ataxia 2, SDCA2 (ATP1B2)
- Oilated Cardiomyopathy, DCM1 (PDK4)
- S Dilated Cardiomyopathy, DCM2 (TTN)
- C Long QT Syndrome (KCNQ1)
- S Muscular Dystrophy (DMD, Cavalier King Charles Spaniel Variant 1)
- S Muscular Dystrophy (DMD Pembroke Welsh Corgi Variant )
- C Limb Girdle Muscular Dystrophy (SGCD, Boston Terrier Variant)
- Centronuclear Myopathy (PTPLA)
- Service Exercise-Induced Collapse (DNM1)
- S Inherited Myopathy of Great Danes (BIN1)
- S Myostatin Deficiency, Bully Whippet Syndrome (MSTN)
- S Myotonia Congenita (CLCN1 Exon 7)
- 🔇 Myotonia Congenita (CLCN1 Exon 23)
- S Myotubular Myopathy 1, X-linked Myotubular Myopathy, XL-MTM (MTM1, Labrador Variant)


- 🕑 Hypocatalasia, Acatalasemia (CAT)
- S Pyruvate Dehydrogenase Deficiency (PDP1)
- 📀 Malignant Hyperthermia (RYR1)
- S Imerslund-Grasbeck Syndrome, Selective Cobalamin Malabsorption (CUBN Exon 53)
- S Imerslund-Grasbeck Syndrome, Selective Cobalamin Malabsorption (CUBN Exon 8)
- 📀 Congenital Myasthenic Syndrome (CHAT)
- 📀 Congenital Myasthenic Syndrome (COLQ)
- Sepisodic Falling Syndrome (BCAN)
- 🔮 Paroxysmal Dyskinesia, PxD (PGIN)
- 😴 Ectodermal Dysplasia, Skin Fragility Syndrome (PKP1)
- 🗸 Ichthyosis, Epidermolytic Hyperkeratosis (KRT10)
- 🗸 Ichthyosis (SLC27A4)
- 🗸 Ichthyosis (NIPAL4)
- S Hereditary Footpad Hyperkeratosis (FAM83G)
- Subscription of the second sec
- S Musladin-Lueke Syndrome (ADAMTSL2)
- Soculocutaneous Albinism, OCA (Pekingese Type)
- Cleft Lip and/or Cleft Palate (ADAMTS20)
- Second Se
- 📀 Osteogenesis Imperfecta, Brittle Bone Disease (COL1A2)
- 📀 Osteogenesis Imperfecta, Brittle Bone Disease (SERPINH1)
- Skeletal Dysplasia 2, SD2 (COL11A2)
- Craniomandibular Osteopathy, CMO (SLC37A2)
- 🛇 Chondrodystrophy, Norwegian Elkhound and Karelian Bear Dog Variant (ITGA10)

### **Coefficient of Inbreeding (COI)**

#### Genetic Result: 1%

Our genetic COI measures the proportion of your dog's genome (her genes) where the genes on the mother's side are identical by descent to those on the father's side. The higher your dog's coefficient of inbreeding (the percentage), the more inbred your dog is.

#### Your Dog's COI



This graph represents where your dog's inbreeding levels fall on a scale compared to both dogs with a similar breed makeup to her (the yellow dotted line) and all purebred dogs (the grey line).

### More on the Science

Embark scientists, along with our research partners at Cornell University, have shown the impact of inbreeding on longevity and fertility and developed a state-of-the-art, peer-reviewed method for accurately measuring COI and predicting average COI in litters.

#### Citations

Sams & Boyko 2019 "Fine-Scale Resolution of Runs of Homozygosity Reveal Patterns of Inbreeding and Substantial Overlap with Recessive Disease Genotypes in Domestic Dogs" (https://www.ncbi.nlm.nih.gov/pubmed/30429214)

Chu et al 2019 "Inbreeding depression causes reduced fecundity in Golden Retrievers" (https://link.springer.com/article/10.1007/s00335-019-09805-4)

Yordy et al 2019 "Body size, inbreeding, and lifespan in domestic dogs" (https://www.semanticscholar.org/paper/Body-size%2C-inbreeding%2C-and-lifespan-indomestic-Yordy-Kraus/61d0fa7a71afb26f547f0fb7ff71e23a14d19d2c)

## About Embark

Embark Veterinary is a canine genetics company offering research-grade genetic tests to pet owners and breeders. Every Embark test examines over 200,000 genetic markers, and provides results for over 200 genetic health conditions, breed identification, clinical tools, and more.

Embark is a research partner of the Cornell University College of Veterinary Medicine and collaborates with scientists and registries to accelerate genetic research in canine health. We make it easy for customers and vets to understand, share and make use of their dog's unique genetic profile to improve canine health and happiness.

Learn more at embarkvet.com

Veterinarians and hospitals can send inquiries to veterinarians@embarkvet.com.